MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Detail) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Jul. 27, 2020	Aug. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accounts receivable			$ 4,522			$ 4,522			$ 6,013
Novartis Institutes for BioMedical Research, Inc.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contract asset		$ 1,500
Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from collaborators		$ 75,000
Collaborative arrangement transaction price	$ 95,100
License fee	75,000
Collaborative arrangement estimated reimbursable service costs	20,100
Accounts receivable			2,000			2,000			1,900
Deferred revenue			17,700			17,700			$ 40,900
Financial advisory fees					$ 1,500
Percent of initial recognition								2.00%
Amortization			$ 200	$ 200		$ 500	$ 500
Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development and sales-based milestone payments to be received	420,000
Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement | Achievement Of Commercial Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development and sales-based milestone payments to be received	$ 300,000